A notable spin-off from the University of Geneva, and materializing from a landscape where every year 41,700 new cancer cases are identified in Switzerland alone, Adiposs is specialized in combatting the clandestine syndrome of cachexia affecting 25% of cancer patients indirectly through muscle and adipose tissue wastage.
Its flagsip product ImageBAT, envisioned to be a paramount diagnostic tool in cancer management, delivers non-invasive visualization and quantification of activated brown fat, which when in excess, propels hypermetabolism correlated to treatment failure in cancer patients. A step further, its conception was largely driven by an ambition to detect cachexia before weight and muscle wastage occur, a previously elusive feat in medical science.
Dr. Andrej Babic, CEO and co-founder, commented: “The completion of the Phase I clinical trial is a major milestone for Adiposs.” Underlying this trial was a meticulous assessment of ImageBAT involving thirty healthy subjects, revealing promising aspects of tolerability and safety without any severe adverse episodes. Equally noteworthy, Dr. Hervé Porchet, Chief Medical Officer, explained: “The levels of exposure to ImageBAT and pharmacokinetics were comparable in healthy subjects and our preclinical studies.”
The serendipitous stride in successfully maneuvering through the pre-clinical development phase, achieving robust proof-of-concept studies in 2020, and securing various accolades and financial backings such as the CHF 100,000 Tech Seed loan from the Foundation for Technological Innovation (FIT), has greatly contributed to Adiposs’ success. The trajectory towards Phase II, slated for 2024 and focusing on patients with advanced lung cancer in Europe, is eagerly anticipated. Reinhard Stary, Chairman of the Board, expressed: “We are very excited at the perspective of using ImageBAT in cancer patients for the first time and making headway on our mission to improve the lives of cancer patients worldwide.”
